Search
Hydroxyurea
go.drugbank.com/drugs/DB01005ApprovedInvestigational[A262596] It was first approved by the FDA in 1998 for the treatment of sickle cell anemia in adults. … need for therapeutic monitoring, and serious side effects of secondary cancer and birth defects.
Aminosalicylic acid
go.drugbank.com/drugs/DB00233ApprovedInvestigationalThe sodium salt of the drug is better tolerated than the free acid.
Categories: Antiinfectives for Systemic Use, Drugs for Treatment of TuberculosisBalsam of Peru
go.drugbank.com/drugs/DB11482ApprovedNutraceuticalVet approvedas safe (GRAS). … [F117] Under the FDA, balsam of Peru is considered as an inactive ingredient to be used for approved drug products[L2878] as well as an approved food additive under the categorization of generally recognized
Mixtures: Keloid Healer Synergy for treatment of keloidsCategories: Compounds used in a research, industrial, or household settingSelexipag
go.drugbank.com/drugs/DB11362ApprovedInvestigationalSelexipag was approved by the United States FDA on December 22, 2015 for the treatment of pulmonary arterial hypertension (PAH) to delay disease progression and reduce risk of hospitalization. … Marketed by Actelion Pharmaceuticals under brand name Uptravi, selexipag and its active metabolite, ACT-333679 (MRE-269), act as agonists of the prostacyclin receptor to increase vasodilation in the pulmonary
Anethole trithione
go.drugbank.com/drugs/DB13853Approvedinhibit carcinogenesis by increasing the activity of electrophile detoxification enzymes [A32619], and even being used as an adjunctive therapy for cholecystitis, gallstone, indigestion, and acute/chronic … for many of these aforementioned functions at this time and is only used in limited regions around the world.
Tofacitinib
go.drugbank.com/drugs/DB08895ApprovedInvestigationalIt is approved by the FDA for treatment of moderate to severe rheumatoid arthritis that responds inadequately to methotrexate or in those who are intolerant to methotrexate. … Besides rheumatoid arthritis, tofacitinib has also been studied in clinical trials for the prevention of organ transplant rejection, and is currently under investigation for the treatment of psoriasis.
Categories: Biologics for Rheumatoid Arthritis TreatmentBimatoprost
go.drugbank.com/drugs/DB00905ApprovedInvestigational[L6910] It was initially approved by the FDA in 2001 for ocular hypertension and later approved for hypothrichosis in 2008, as eyelash growth became a desirable adverse effect for patients using this drug … Bimatoprost, marketed by Allergan, is administered in both the ophthalmic solution and implant form.
Mixtures: BIMAPROS T, BEMATORİN-T 0,3 MG + 5 MG/1 ML GÖZ DAMLASI, ÇÖZELTİ, 1 ADETNonivamide
go.drugbank.com/drugs/DB11324ApprovedIt is naturally found in chili peppers but manufactured to produce a synthetic form for various pharmacologic preparations [L2641]. … The structures of [DB06774] and nonivamide differ only slightly with respect to the fatty acid moiety of the side chain (8-methyl nonenoic acid versus nonanoic acid) [F31].
Mixtures: Finalgon - Salbe, Nonivamid + Nicoboxil Zentiva 4 mg/g + 25 mg/g SalbeIopodic acid
go.drugbank.com/drugs/DB09333ApprovedWithdrawn[A32080] Due to its particular structure, it presents a high degree of lipid solubility and a radiopaque property. It was developed and filed to the FDA by the company BRACCO. … On September 22, 1981, ipodate was submitted again by the company Schering AG but it is currently under an inactive status.[L1082]
Categories: Compounds used in a research, industrial, or household settingFostemsavir
go.drugbank.com/drugs/DB11796ApprovedInvestigational[A215057] Fostemavir is the first attachment inhibitor to receive FDA approval, granted in July 2020 for use in combination with other antiretrovirals in highly treatment-experienced patients with multidrug-resistant … orthogonal therapies) for the treatment of HIV-1 patients with resistant infections.
Categories: Antivirals for Systemic Use, Antiinfectives for Systemic Use